ProCE Banner Activity

Considerations for Selecting Systemic Therapy for Patients with RCC: Adjuvant Approaches and First-Line Therapy for Advanced Disease

Slideset Download
Download these slides from a live webinar for the most recent data on the use of adjuvant therapy for nonmetastatic RCC and the optimal first line treatment options for patients with advanced RCC.

Released: June 05, 2022

Expiration: June 04, 2023

Share

Faculty

Naomi B. Haas

Naomi B. Haas, MD

Professor
Division of Hematology/Oncology
Director
Kidney Cancer and Prostate Cancer Clinical Research Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Provided by

Provided by National Comprehensive Cancer Network.
ProCE Banner

Supporters

Supported by educational grants from

AVEO Pharmaceuticals, Inc.

Eisai Inc.

Exelixis

Merck Sharp & Dohme Corp.

Pfizer, Inc.

Faculty Disclosure

Primary Author

Naomi B. Haas, MD

Professor
Division of Hematology/Oncology
Director
Kidney Cancer and Prostate Cancer Clinical Research Programs
Abramson Cancer Center
University of Pennsylvania
Philadelphia, Pennsylvania

Naomi B. Haas, MD, has disclosed that she has received consulting fees from AVEO, Eisai, Merck, and Roche Genentech.